The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
Open accessAbstract
BACKGROUND: In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk of coronary events, but the effects on mortality from coronary heart disease and overall mortality have remained uncertain. METHODS: In a double-blind, randomized trial, we compared the effects of pravastatin (40 mg daily) with those of a placebo over a mean follow-up period of 6.1 years in 9014 patients who were 31 to 75 years of age. The patients had a history of myocardial infarction or hospitalization for unstable angina and initial plasma total cholesterol levels of 155 to 271 mg per deciliter. Both groups received advice on following a cholesterol-lowering diet. The primary study outcome was mortality from coronary heart disease. RESULTS: Death from coronary heart disease occurred in 8.3 percent of the patients in the placebo group and 6.4 percent of those in the pravastatin group, a relative reduction in risk of 24 percent (95 percent confidence interval, 12 to 35 percent; P<0.001). Overall mortality was 14.1 percent in the placebo group and 11.0 percent in the pravastatin group (relative reduction in risk, 22 percent; 95 percent confidence interval, 13 to 31 percent; P<0.001). The incidence of all cardiovascular outcomes was consistently lower among patients assigned to receive pravastatin; these outcomes included myocardial infarction (reduction in risk, 29 percent; P<0.001), death from coronary heart disease or nonfatal myocardial infarction (a 24 percent reduction in risk, P<0.001), stroke (a 19 percent reduction in risk, P=0.048), and coronary revascularization (a 20 percent reduction in risk, P<0.001). The effects of treatment were similar for all predefined subgroups. There were no clinically significant adverse effects of treatment with pravastatin. CONCLUSIONS: Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A large body of evidence indicates that statin-based strategies convey similar LDL-C lowering and relative cardiovascular risk reduction in patients with and those without T2DM.102–112”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [103]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data from RCTs and meta-analyses indicate that routine early use of high-intensity statin therapy is associated with rapid and sustained clinical benefits [438-442].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [442]
Experimental — accuracy not yet measuredIn the citing paper
“Although healthy lifestyle habits remain a cornerstone of T2DM management, trial data have confirmed the additional benefits of statin therapy in the primary and secondary prevention of CAD.13,102–112”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [103]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9-45% in patients with CAD.22,180”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [22]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9-45% in patients with CAD. 368,369”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [369]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9e45% in patients with CAD.368,369”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [369]
In the citing paper
“It was demonstrated in the REACH registry, a registry study on patients with ASCVD or overlapping risks factors for ASCVD, that approximately 16% registered cases are complicated with two or more ASCVD757).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [757]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,851
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960
EUROASPIRE Study Group (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015136 · Cited by 665
Chen, Z., Peto, R., Collins, R., MacMahon, S. W., Lu, J., & Li, W. (1991) · BMJ · doi:10.1136/bmj.303.6797.276 · Cited by 537
Research works printed but not linked: 4
- Peto R, 1985, Circulation, 72, 451
- Keech A, 1992, Postgrad Med J, 68, 870
- 1994, Lancet, 344, 1383
- Keech A, 1998, Atherosclerosis, 136, S31
Cited by
Sorted by citations
Items 401–500 of 1,037
Secondary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults
Fleg, J. L., Forman, D. E., Berra, K. A., Bittner, V., Blumenthal, J. A., Chen, M. A., Cheng, S. C., Kitzman, D. W., Maurer, M. S., Rich, M. W., et al. (2013) · Circulation · doi:10.1161/01.cir.0000436752.99896.22 · Cited by 225
Evidence for Statin Pleiotropy in Humans
Liu, P., Liu, Y.-W., Lin, L.-J., Chen, J.-H., & Liao, J. K. (2008) · Circulation · doi:10.1161/circulationaha.108.813311 · Cited by 224
Use of Health Services by Previously Uninsured Medicare Beneficiaries
McWilliams, J. M., Meara, E. R., Zaslavsky, A. M., & Ayanian, J. Z. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa067712 · Cited by 223
Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins
Shah, P. K., Kaul, S., Nilsson, J. Å., & Cercek, B. (2001) · Circulation · doi:10.1161/hc4401.098467 · Cited by 223
McFarlane, S. I., Jacober, S. J., Winer, N., Kaur, J., Castro, J. P., Wui, M. A., Gliwa, A., von Gizycki, H., & Sowers, J. R. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.718 · Cited by 222
A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin
White, C. M. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127000204200902 · Cited by 221
Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia
Marks, D., Wonderling, D. E., Thorogood, M., Lambert, H., Humphries, S. E., & Neil, H. A. W. (2002) · BMJ · doi:10.1136/bmj.324.7349.1303 · Cited by 221
An application of propensity score matching using claims data
Seeger, J. D., Williams, P. L., & Walker, A. M. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1062 · Cited by 218
Krumholz, H. M., Anderson, J. L., Bachelder, B. L., Fesmire, F. M., Fihn, S. D., Foody, J. M., Ho, P. M., Kosiborod, M., Masoudi, F. A., & Nallamothu, B. K. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.012 · Cited by 218
Statins and Liver Toxicity: A Meta‐Analysis
de Denus, S., Spinler, S. A., Miller, K., & Peterson, A. M. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.6.584.34738 · Cited by 218
How to develop cost-conscious guidelines
Eccles, M., & Mason, J. M. (2001) · Health Technology Assessment · doi:10.3310/hta5160 · Cited by 218
Libby, P. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01339-4 · Cited by 218
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
Tanaka, K., Ishikawa, Y., Yokoyama, M., Origasa, H., Matsuzaki, M., Saito, Y., Matsuzawa, Y., Sasaki, J., Oikawa, S., Hishida, H., et al. (2008) · Stroke · doi:10.1161/strokeaha.107.509455 · Cited by 217
van Heek, M., Farley, C., Compton, D. S., Hoos, L. M., & Davis, H. R. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704260 · Cited by 217
New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders
McKenney, J. M. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.7.697 · Cited by 217
Statin myopathy: A common dilemma not reflected in clinical trials
Fernandez, G., Spatz, E. S., Jablecki, C. K., & Phillips, P. S. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78a.10073 · Cited by 217
New Tools for Coronary Risk Assessment
Pearson, T. A. (2002) · Circulation · doi:10.1161/hc0702.103727 · Cited by 216
Drug-Induced Hyperglycaemia and Diabetes
Fathallah, N., Slim, R., Larif, S., Hmouda, H., & Salem, C. B. (2015) · Drug Safety · doi:10.1007/s40264-015-0339-z · Cited by 215
Reid, I. R., Hague, W. E., Emberson, J., Baker, J., Tonkin, A. M., Hunt, D. U., MacMahon, S. W., & Sharpe, N. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04042-3 · Cited by 215
ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction
(2004) · Circulation · doi:10.1161/circ.110.9.e82 · Cited by 213
Health of Previously Uninsured Adults After Acquiring Medicare Coverage
McWilliams, J. M., Meara, E. R., Zaslavsky, A. M., & Ayanian, J. Z. (2007) · JAMA · doi:10.1001/jama.298.24.2886 · Cited by 211
Hodis, H. N., & Mack, W. J. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000591 · Cited by 211
Baigent, C., Landray, M., Leaper, C., Altmann, P., Armitage, J., Baxter, A., Cairns, H., Collins, R., Foley, R. N., Frighi, V., et al. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.11.015 · Cited by 211
Pan, W., Pintar, T., Anton, J. M., Lee, V., Vaughn, W. K., & Collard, C. D. (2004) · Circulation · doi:10.1161/01.cir.0000138316.24048.08 · Cited by 211
Statin‐Associated Adverse Cognitive Effects: Survey Results from 171 Patients
Evans, M. A., & Golomb, B. A. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.7.800 · Cited by 209
Howard, W. J. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79115-7 · Cited by 209
Ferro, D., Parrotto, S., Basili, S., Alessandri, C., & Violi, F. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00771-3 · Cited by 209
Association of Statin Therapy with Outcomes of Acute Coronary Syndromes: The GRACE Study
Spencer, F. A., Allegrone, J., Goldberg, R. J., Gore, J. M., Fox, K. A. A., Granger, C. B., Mehta, R. H., Brieger, D. B., & and the GRACE Investigators* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-11-200406010-00006 · Cited by 209
Woolf, S. H. (2005) · The Annals of Family Medicine · doi:10.1370/afm.406 · Cited by 208
Guedeney, P., Giustino, G., Sorrentino, S., Claessen, B. E., Camaj, A., Kalkman, D. N., Vogel, B., Sartori, S., De Rosa, S., Baber, U., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehz430 · Cited by 208
Psaty, B. M., Anderson, M. L., Kronmal, R. A., Tracy, R. P., Orchard, T. J., Fried, L. P., Lumley, T., Robbins, J. A., Burke, G. L., Newman, A. B., et al. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52455.x · Cited by 208
Lipid-lowering for peripheral arterial disease of the lower limb
Aung, P. P., Maxwell, H., Jepson, R. G., Price, J. F., & Leng, G. C. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000123.pub2 · Cited by 208
Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions
Chan, A. W., Bhatt, D. L., Chew, D. P., Reginelli, J. P., Schneider, J. P., Topol, E. J., & Ellis, S. G. (2003) · Circulation · doi:10.1161/01.cir.0000060541.18923.e9 · Cited by 207
Statins as Antithrombotic Drugs
Violi, F., Calvieri, C., Ferro, D., & Pignatelli, P. (2013) · Circulation · doi:10.1161/circulationaha.112.145334 · Cited by 206
Endres, M. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600116 · Cited by 205
Rosuvastatin: A Highly Effective New HMG‐CoA Reductase Inhibitor
OLSSON, A. G., McTaggart, F., & Raza, A. (2002) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2002.tb00099.x · Cited by 204
Waters, D. D., Guyton, J. R., Herrington, D. M., McGowan, M. P., WENGER, N. K., & Shear, C. L. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.09.031 · Cited by 201
Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?
von Haehling, S., & Anker, S. D. (2004) · Heart · doi:10.1136/hrt.2004.042515 · Cited by 201
Halcox, J., & Deanfield, J. E. (2004) · Circulation · doi:10.1161/01.cir.0000129500.29229.92 · Cited by 200
Weverling-Rijnsburger, A. W. E., Jonkers, I. J. A. M., van Exel, E., Gussekloo, J., & Westendorp, R. G. J. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.13.1549 · Cited by 199
Physician Follow-up and Provider Continuity Are Associated With Long-term Medication Adherence
Brookhart, M. A. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.8.847 · Cited by 198
Chest radiography for the diagnosis of acute aortic syndrome
Kodolitsch, Y. V., Nienaber, C. A., Dieckmann, C., Schwartz, A. G., Hofmann, T., Brekenfeld, C., Nicolas, V., Berger, J., & Meinertz, T. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.030 · Cited by 198
National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand
Tonkin, A. M., Barter, P. J., Best, J. D., Boyden, A. N., Furler, J., Hossack, K., SULLIVAN, D. R., Thompson, P. L., Vale, M. J., Cooper, C., et al. (2005) · Heart Lung and Circulation · doi:10.1016/j.hlc.2005.10.010 · Cited by 197
Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., & Kawamori, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0222 · Cited by 197
Boekholdt, S. M., Arsenault, B. J., Hovingh, G. K., Mora, S., Pedersen, T. R., LaRosa, J. C., Welch, K. M. A., Amarenco, P., DeMicco, D. A., Tonkin, A. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002670 · Cited by 196
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000133317.49796.0e · Cited by 196
Are lipid-lowering drugs also antiarrhythmic drugs?
Mitchell, L. B., Powell, J. L., Gillis, A. M., Kehl, V., & Hallstrom, A. P. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00498-4 · Cited by 196
Collinson, J. (2000) · European Heart Journal · doi:10.1053/euhj.1999.1995 · Cited by 196
Calcium deposition within coronary atherosclerotic lesion: Implications for plaque stability
Jinnouchi, H., Sato, Y., Sakamoto, A., Cornelissen, A., Mori, M., Kawakami, R., Gadhoke, N. V., Kolodgie, F. D., Virmani, R., & Finn, A. V. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.05.017 · Cited by 195
Economics notes: Opportunity cost
Palmer, S., & Raftery, J. P. (1999) · BMJ · doi:10.1136/bmj.318.7197.1551 · Cited by 195
Clinically relevant differences between the statins: implications for therapeutic selection
Chong, P. H., Seeger, J. D., & Franklin, C. M. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00870-1 · Cited by 195
Mechanisms of oxidative stress and vascular dysfunction
Nedeljkovic, Z. S., Gokce, N., & Loscalzo, J. (2003) · Postgraduate Medical Journal · doi:10.1136/pmj.79.930.195 · Cited by 195
Do statins cause cancer? A meta-analysis of large randomized clinical trials
Bjerre, L. M., & LeLorier, J. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00705-7 · Cited by 194
Diagnosis, prevention, and intervention for the metabolic syndrome
SCOTT, C. L. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00507-1 · Cited by 193
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192
Validation of the Archimedes Diabetes Model
Eddy, D. M., & Schlessinger, L. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3102 · Cited by 192
Effect of statins on toll-like receptors: a new insight to pleiotropic effects
Bahrami, A., Parsamanesh, N., Atkin, S. L., Banach, M., & Sahebkar, A. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.014 · Cited by 192
Pfisterer, M. E. (2004) · Circulation · doi:10.1161/01.cir.0000140983.69571.ba · Cited by 192
Vijan, S. S., & Hayward, R. A. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-8-200404200-00013 · Cited by 192
Priori, S. G. (2002) · EP Europace · doi:10.1053/eupc.2001.0214 · Cited by 192
Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease
Tonelli, M. A., Isles, C., Craven, T. E., Tonkin, A., Pfeffer, M. A., Shepherd, J., Sacks, F. M., Furberg, C. D., Cobbe, S. M., Simes, J. R., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.517565 · Cited by 190
Statins and Intracerebral Hemorrhage
Hackam, D. G., Woodward, M., Newby, L. K., Bhatt, D. L., Shao, M., Smith, E. E., Donner, A., Mamdani, M., Douketis, J. D., Arima, H., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.055269 · Cited by 189
Pleiotropic effects of statins
Vasnawala, H., Kavalipati, N., Shah, J., & Ramakrishan, A. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.163106 · Cited by 189
Trøseid, M. (2004) · European Heart Journal · doi:10.1016/j.ehj.2003.12.006 · Cited by 188
Wang, N., Fulcher, J., Abeysuriya, N., Park, L., Kumar, S., Di Tanna, G. L., Wilcox, I., Keech, A., Rodgers, A., & Lal, S. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30388-2 · Cited by 187
Innate and Adaptive Inflammation as a Therapeutic Target in Vascular Disease
Tousoulis, D., Psarros, C., Demosthenous, M., Patel, R., Antoniades, C., & Stefanadis, C. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.054 · Cited by 187
Hypertension and coronary heart disease
Escobar, E. (2002) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001345 · Cited by 187
Statin Therapy in the Prevention of Recurrent Cardiovascular Events
Gutierrez, J., Ramı́rez, G., Rundek, T., & Sacco, R. L. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.2145 · Cited by 186
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.185752 · Cited by 185
U.S. Preventive Services Task Force* (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-11-200806030-00007 · Cited by 185
Beyond lipid-lowering: effects of statins on endothelial nitric oxide
Laufs, U. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0556-0 · Cited by 185
Giugliano, R. P., Pedersen, T. R., Saver, J. L., Sever, P. S., Keech, A. C., Bohula, E. A., Murphy, S. A., Wasserman, S. M., Honarpour, N., Wang, H., et al. (2020) · Stroke · doi:10.1161/strokeaha.119.027759 · Cited by 184
Patient, Physician, and Payment Predictors of Statin Adherence
Chan, D. C., Shrank, W. H., Cutler, D., Jan, S., Fischer, M. A., Liu, J., Avorn, J., Solomon, D. H., Brookhart, M. A., & Choudhry, N. K. (2010) · Medical Care · doi:10.1097/mlr.0b013e3181c132ad · Cited by 184
Amarenco, P., Bogousslavsky, J., Callahan, A., Goldstein, L. B., Hennerici, M. G., Sillsen, H., Welch, M. A., & Zivin, J. A. (2003) · Cerebrovascular Diseases · doi:10.1159/000072562 · Cited by 184
Coronary Heart Disease in Patients With Low LDL-Cholesterol
Sacks, F. M., Tonkin, A. M., Craven, T. E., Pfeffer, M. A., Shepherd, J., KEECH, A. C., Furberg, C. D., & Braunwald, E. (2002) · Circulation · doi:10.1161/01.cir.0000012918.84068.43 · Cited by 184
Yang, X., Xiong, X., Wang, H., & Wang, J. (2014) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2014/204840 · Cited by 183
Cholesterol and atherosclerosis
Libby, P. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00161-x · Cited by 183
Davis, H. R., Compton, D. S., Hoos, L., & Tetzloff, G. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1201.100260 · Cited by 182
Statin Therapy in Stroke Prevention: A Meta-analysis Involving 121,000 Patients
O’Regan, C., Wu, P., Arora, P., Perri, D., & Mills, E. J. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.06.033 · Cited by 182
Houslay, E. S., Cowell, S. J., Prescott, R. J., Reid, J. H., Burton, J., Northridge, D. B., Boon, N. A., & Newby, D. E. (2006) · Heart · doi:10.1136/hrt.2005.080929 · Cited by 182
Effect of statin therapy on colorectal cancer
Bardou, M., Barkun, A. N., & Martel, M. (2010) · Gut · doi:10.1136/gut.2009.190900 · Cited by 182
Statin Use and Breast Cancer: Prospective Results From the Women's Health Initiative
Cauley, J. A., McTiernan, A., Rodabough, R. J., LaCroix, A. Z., Bauer, D. C., Margolis, K. L., Paskett, E. D., Vitolins, M. Z., Furberg, C. D., & Chlebowski, R. T. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj188 · Cited by 182
Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis
Preiss, D., Tikkanen, M. J., Welsh, P., Ford, I., Lovato, L. C., Elam, M. B., LaRosa, J. C., DeMicco, D. A., Colhoun, H. M., Goldenberg, I., et al. (2012) · JAMA · doi:10.1001/jama.2012.8439 · Cited by 181
Comparative Tolerability of the HMG-CoA Reductase Inhibitors
Farmer, J. A., & Torre‐Amione, G. (2000) · Drug Safety · doi:10.2165/00002018-200023030-00003 · Cited by 181
Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors
Howard, B. V., Best, L. G., Galloway, J. M., Howard, W. J., Jones, K., Lee, E. T., Ratner, R. E., Resnick, H. E., & Devereux, R. B. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1299 · Cited by 180
Nikolsky, E., Grines, C. L., Cox, D. A., García, E., Tcheng, J. E., Sadeghi, M., Mehran, R., Lansky, A. J., Na, Y., & Stone, G. W. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.066 · Cited by 179
Relationship Between Quality of Care and Racial Disparities in Medicare Health Plans
Trivedi, A. N., Zaslavsky, A. M., Schneider, E. C., & Ayanian, J. Z. (2006) · JAMA · doi:10.1001/jama.296.16.1998 · Cited by 179
Long-term Medication Adherence after Myocardial Infarction: Experience of a Community
Shah, N. D., Dunlay, S. M., Ting, H. H., Montori, V. M., Thomas, R. J., Wagie, A. E., & Roger, V. L. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.12.021 · Cited by 179
Statins enhance postischemic hyperemia in the skin circulation of hypercholesterolemic patients
Binggeli, C., Spieker, L. E., Corti, R., Sudano, I., Stojanovic, V., Hayoz, D., Lüscher, T. F., & Noll, G. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00505-9 · Cited by 179
Bays, H. E., Ose, L., Fraser, N., Tribble, D. L., Quinto, K., Reyes, R., Johnson‐Levonas, A. O., Sapre, A., & Donahue, S. R. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.11.016 · Cited by 178
Medical Therapy for Heart Failure Caused by Ischemic Heart Disease
Elgendy, I. Y., Mahtta, D., & Pepine, C. J. (2019) · Circulation Research · doi:10.1161/circresaha.118.313568 · Cited by 179
Statin therapy is associated with lower mortality among patients with severe heart failure
Mozaffarian, D., Nye, R., & Levy, W. C. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.01.039 · Cited by 178
Preventing Coronary Artery Disease by Lowering Cholesterol Levels
Steinberg, D. H., & Gotto, A. M. (1999) · JAMA · doi:10.1001/jama.282.21.2043 · Cited by 178
McGuire, D. K. (2000) · European Heart Journal · doi:10.1053/euhj.2000.2317 · Cited by 178
Wassmann, S., Faul, A., Hennen, B., Scheller, B., Böhm, M., & Nickenig, G. (2003) · Circulation Research · doi:10.1161/01.res.0000099503.13312.7b · Cited by 177
Diabetes mellitus and stroke: A clinical update
Tun, N. N., Arunagirinathan, G., Munshi, S. K., & Pappachan, J. M. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i6.235 · Cited by 177
The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease
Lee, K. W., & Lip, G. Y. H. (2003) · QJM · doi:10.1093/qjmed/hcg092 · Cited by 176
良一, 橋., Kim, H.-S., Jeong, T.-S., Bok, S.-H., & Park, Y.-B. (2001) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200112000-00017 · Cited by 175
MRI of carotid atherosclerosis: clinical implications and future directions
Underhill, H. R., Hatsukami, T. S., Fayad, Z. A., Fuster, V., & Yuan, C. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.246 · Cited by 175
Metadata
- Authors
- The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1998-11-05
- Volume
- 339
- Issue
- 19
- Pages
- 1349-1357
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W38523360
- Cited by
- 5,261
- References
- 21
- Citations by year
- 2026: 19 · 2025: 24 · 2024: 57 · 2023: 53 · 2022: 60 · 2021: 58 · 2020: 72 · 2019: 82 · 2018: 81 · 2017: 94 · 2016: 114 · 2015: 111 · 2014: 118 · 2013: 167 · 2012: 147
- FWCI
- 312.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- pravastatin, coronary artery disease, statin therapy, cholesterol-lowering therapy, cardiovascular mortality, myocardial infarction, unstable angina, stroke, coronary revascularization, total cholesterol, secondary prevention, lipid-lowering diet
- MeSH terms
- Adult, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Humans, Lipids, Male, Middle Aged, Mortality, Myocardial Infarction, Risk, Incidence, Pravastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
